NEW YORK, NY / ACCESSWIRE / July 14, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:
Garrison Capital Inc. (NASDAQ:GARS)
The investigation concerns whether Garrison Capital and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Garrison Capital to Portman Ridge Finance Corporation. Following the proposed transaction, Garrison Capital shareholders are expected to own approximately 41.6% of the combined company. If you are a Garrison Capital shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/garrison-capital-inc-gars-portman-ridge-stock-merger/.
Invitae Corporation (NYSE:NVTA)
The investigation concerns whether Invitae and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed merger between Invitae and ArcherDX. Under the terms of merger, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, and up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, with the overall transaction valued at approximately $1.4 billion. If you are an Invitae shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/invitae-corporation-nvta-stock-merger-archerdx/.
Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN)
The investigation concerns whether Rexahn Pharmaceuticals and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection the merger between Rexahn Pharmaceuticals and Ocuphire Pharma, Inc. If you are a Rexahn Pharmaceuticals shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/rexahn-pharmaceuticals-inc-rexn-stock-merger-ocuphire/.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
SOURCE: Halper Sadeh LLP
View source version on accesswire.com:
https://www.accesswire.com/597445/INVESTIGATION-ALERT-Halper-Sadeh-LLP-is-Investigating-Whether-the-Following-Mergers-are-Fair-to-Shareholders-Investors-are-Encouraged-to-Contact-the-Firm--GARS-NVTA-REXN
